APA (7th ed.) Citation

Schneeweiss, A., Ettl, J., Lüftner, D., Beckmann, M. W., Belleville, E., Fasching, P. A., . . . Brucker, S. Y. (2021). Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer: Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". The breast, 55, . https://doi.org/10.1016/j.breast.2020.12.007

Chicago Style (17th ed.) Citation

Schneeweiss, Andreas, et al. "Corrigendum to "Initial Experience with CDK4/6 Inhibitor-based Therapies Compared to Antihormone Monotherapies in Routine Clinical Use in Patients with Hormone Receptor Positive, HER2 Negative Breast Cancer: Data from the PRAEGNANT Research Network for the First 2 Years of Drug Availability in Germany"." The Breast 55 (2021). https://doi.org/10.1016/j.breast.2020.12.007.

MLA (9th ed.) Citation

Schneeweiss, Andreas, et al. "Corrigendum to "Initial Experience with CDK4/6 Inhibitor-based Therapies Compared to Antihormone Monotherapies in Routine Clinical Use in Patients with Hormone Receptor Positive, HER2 Negative Breast Cancer: Data from the PRAEGNANT Research Network for the First 2 Years of Drug Availability in Germany"." The Breast, vol. 55, 2021, https://doi.org/10.1016/j.breast.2020.12.007.